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Majortraumaresultsinastronginﬂammatoryresponseininjuredtissue.Thisposttraumatichyperinﬂammationhasbeenimplied
in the adverse events leading to a breakdown of host defense mechanisms and ultimately to delayed organ failure. Ligands to
peroxisomeproliferator-activatedreceptors(PPARs)haverecentlybeenidentiﬁedaspotentmodulatorsofinﬂammationinvarious
acute and chronic inﬂammatory conditions. The main mechanism of action mediated by ligand binding to PPARs is the inhibition
ofthenucleartranscriptionfactorNF-κB,leadingtodownregulationofdownstreamgenetranscription,suchasforgenesencoding
proinﬂammatory cytokines. Pharmacological PPAR agonists exert strong anti-inﬂammatory properties in various animal models
of tissue injury, including central nervous system trauma, ischemia/reperfusion injury, sepsis, and shock. In addition, PPAR
agonists have been shown to induce wound healing process after tissue trauma. The present review was designed to provide an
up-to-date overview on the current understanding of the role of PPARs in the pathophysiology of the inﬂammatory response
after major trauma. Therapeutic options for using recombinant PPAR agonists as pharmacological agents in the management of
posttraumatic inﬂammation will be discussed.
1.Introduction
Severe trauma still represents the most frequent cause of
death in people below the age of 40 years [1]. Despite
research eﬀorts and improved intensive care of patients with
trauma, no causal protective therapy is currently available,
and the clinical outcome of multiply injured patients is still
poor. Following severe tissue injury, a series of inﬂammatory
eventsis initiated thathavetobe tightly orchestratedto guar-
antee eﬃcient tissue repair. A controlled posttraumatic in-
ﬂammatoryresponseconsistsoflimitedreleaseofproinﬂam-
matorymediatorsandrecruitmentofimmunecellsthatcon-
tribute to wound healing and restoration of organ function
[2]. If trauma is severe or if additional “second hit” insults
occur, this primary protective activation of the immune
system may turn to an uncontrolled inﬂammatory response
which might cause additional tissue damage and impair the
outcome of trauma [3, 4]. In addition, early posttraumatic
hypoxia and hypotension due to the interruption of the
bloodﬂowmayinduceischemiaandreperfusioninjuriesand
increase the extent of harmful events [5].
Peroxisome proliferator-activated receptors (PPARs) are
nuclear membrane-associated transcription factors which
have recently been shown to possess profound anti-inﬂam-
matory functions in a broad ﬁeld of injury-associated condi-
tions including trauma of the central nervous system (CNS),
ischemia/reperfusion injury, sepsis, and shock [6–8]. The
present review outlines the current understanding of PPAR-
mediatedanti-inﬂammatorymechanismsanddiscussesboth
opportunities and limitations of PPAR ligands as potential
treatment strategy in trauma.2 PPAR Research
2. Peroxisome Proliferator-Activated
Receptors(PPARs)
PPARs are ligand-activated membrane-associated transcrip-
tion factors belonging to the nuclear hormone receptor
family. To date, three subtypes of PPARs have been identiﬁed
invariousspecies,PPARα,PP ARβ/δ,andPP ARγ,thatexhibit
diﬀerential tissue distributions and ligand speciﬁcities [9,
10]. Whereas PPARβ/δ is ubiquitously expressed in a wide
range of cells, PPARα is found in tissues with high fatty acid
catabolism such as brown adipose tissue, liver, heart, kidney,
and skeletal muscle, and PPARγ is mainly expressed in the
brown and white adipose tissue [10]. A wide range of natural
and synthetic compounds can function as PPAR ligands. The
natural agonists include fatty acids and fatty acid derivates,
mainly eicosanoids, that can bind to and activate all three
PPARsubtypes.Withrespecttothesyntheticligands,ﬁbrates
as lipid-lowering drugs function as PPARα agonists, and
glitazones, a class of oral antidiabetic agents, have been de-
scribed to bind to PPARγ [9, 11].
PPARs are activated by heterodimerization with the re-
tinoid-X receptor (RXR) into biologically active transcrip-
tion factors. PPAR-RXR heterodimers then bind to speciﬁc
DNA sequences, known as peroxisome proliferator response
elements (PPREs), in the promotor region of target genes,
therebyactingasatranscriptionalregulator[12].Inaddition,
PPARα and PPARγ are also capable of regulating gene ex-
pressionindependentlyofbindingtoPPREs.Theactivityofa
numberoftranscriptionfactors,forexampleNF-κB(n uc lear
factor-κB), AP-1 (activator protein-1), and STAT-1 (signal
transducer and activator of transcription), can be inhibited
by PPARs either via direct interaction or by competition
for limited supplies of coactivators [11, 13]. This function
is important in regard to the anti-inﬂammatory properties
of PPARs since proinﬂammatory gene expression is mainly
aﬀected by this direct repression of transcription factors.
Since their ﬁrst description, PPARs have been implicated
in numerous biological processes and diseases. They play a
central role in the regulation of glucose, lipid, and lipopro-
teinmetabolism,andPPARagonistsareestablisheddrugsfor
treatmentofdiabetes(glitazones)anddyslipidemia(ﬁbrates)
[14]. Furthermore, angiogenesis, cellular diﬀerentiation and
proliferation as well as apoptosis are mediated by PPARs,
so that PPARs were suggested to contribute to tissue repair
and cancer-related pathways [15, 16]. More recent studies
could demonstrate an additional involvement of PPARs in
senescence-related diseases, in the regulation of male and
female fertility, and in cardiovascular conditions like athero-
sclerosis [17, 18].
In regard to the immune system, PPARs have been iden-
tiﬁed as crucial regulators of inﬂammatory gene expression.
V a r i o u si m m u n ec e l l sw e r es h o w nt oe x p r e s sP P A R si n c l u d -
ing dendritic cells, monocytes, macrophages, B- and T-lym-
phocytes, and vascular endothelial cells [11]. At the site
of inﬂammation, PPARβ/δ ligands reduce the expression
of adhesion molecules by endothelial cells and decrease
the release of cytokines and chemokines by macrophages.
PPARα activation could be linked to inhibited production
of proinﬂammatory cytokines from TH1 cells and increased
release of anti-inﬂammatory cytokines from TH2 cells [19].
These numerous anti-inﬂammatory properties of PPARs
have suggested a central role of PPAR activation in attenuat-
ingtheinﬂammatoryresponseaftertraumaandtissueinjury.
3. The Role PPARs in CentralNervous
System Trauma
TraumaticinjuryoftheCNSremainsamajorhealthproblem
worldwide and represents one of the leading causes of death
and persisting neurological impairment in industrialized
countries [1, 20]. Brain damage after traumatic brain
injury (TBI) is determined by a combination of primary
and secondary insults [21, 22]. While the primary injury
is induced by the mechanical impact to the skull and
brain, secondary brain injury results from an uncontrolled
neuroinﬂammatory response within the injured brain.
Recent experimental studies have indicated that acti-
vation of PPARs might represent a promising therapeutic
strategy for counteracting this deleterious posttraumatic
inﬂammation [23, 24]. PPAR expression has been described
in intracerebral and spinal vascular endothelial cells, neu-
rons, astrocytes, and oligodendrocytes [25, 26]. Interestingly,
two recent studies could show an upregulation of cortical
PPARexpressionbothinexperimentalmodelsofCNSinjury,
and in the brain of head-injured patients [27–29].
The key role of PPARs in attenuating neuroinﬂam-
mation has been examined in multiple models of stroke,
ischemia/reperfusion injury and CNS trauma as well as in
chronic brain disorders like Parkinson’s and Alzheimer’s
disease [6, 30]. In these studies [30–32], PPAR activation
was shown to induce neuroprotection through three distinct
main mechanisms, as outlined schematically in Figure 1.
First, the cerebral inﬂammatory response itself was modu-
lated by PPAR-induced inhibition of macrophage/monocyte
activation and proinﬂammatory cytokine release and sup-
pressed upregulation of cellular adhesion molecules [33, 34].
Second, PPARs were able to modulate oxidative stress in the
brain, a signiﬁcant component enhancing the inﬂammatory
cascade and secondary brain injury; activation of PPARs led
to reduced production of reactive oxygen species and nitric
oxide and increased the release of antioxidants around the
injured tissue [35, 36]. Finally, PPARs have been shown to
delay neuronal apoptosis and decrease lesion sizes by the
inhibition of proapoptotic mediators [27, 37].
As mentioned above, PPARs act by repressing central
inﬂammatory transcription factors like NF-κBo rA P - 1[ 11].
This mechanism is likely to underlie the described anti-
inﬂammatory eﬀe c to fP P A Ra c t i v a t i o na f t e rC N St r a u m a
and seems to be responsible for the reduced expression of
several key downstream inﬂammatory genes in the injured
CNS [32].
Genovese et al. have examined the eﬀect of PPAR-α gene
depletion in a mouse model of spinal cord injury: PPAR-
α−/− miceshowedsigniﬁcantlyaugmentedinjuryparameters
such as edema, neutrophil inﬁltration, and apoptosis [38].
Moreover, the therapeutic eﬀect of glucocorticoids has been
compared in PPAR-α−/− and wild-type mice [39]. Since
the anti-inﬂammatory properties of glucocorticoids werePPAR Research 3
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Figure 1: Overview of the anti-inﬂammatory and neuroprotective eﬀects of selected PPAR agonists in central nervous system (CNS) injury,
as exempliﬁed in the setting of traumatic brain injury. See text for detailed explanations. Abbreviations: PPAR, peroxisome proliferator-
activated receptor; 2-AG, 2-arachidonyl glycerol; NF-κB, nuclear factor-κB; CNS, central nervous system.
markedly weakened in PPAR-α−/− mice, it was hypothesized
that PPAR-α could contribute to the anti-inﬂammatory
activity of glucocorticoids in CNS trauma [39].
Paying attention to the above mentioned crucial role
of PPARs in neuroprotection, pharmacological agonism to
PPARs has been of particular interest to the neuroscience
community in recent years (Figure 1)[ 33, 40]. Originally,
PPAR-α ligands have been described as highly promising
anti-inﬂammatory drugs (reviewed in [6]). In a rat model of
traumatic brain injury, the PPAR-α agonist fenoﬁbrate was
revealed to signiﬁcantly ameliorate pathophysiology after in-
jury including an improvement of neurological scores and
a reduction of brain edema [41]. In addition, fenoﬁbrate
showed antioxidant eﬀects demonstrated by decrease of in-
tracerebral markers of oxidative stress [36]. A study from the
same group assessed a synergistical eﬀect of a combination
therapy with fenoﬁbrate and simvastatin, a lipid-lowering
drug [42]. The administration of these pharmacological
compounds in combination after TBI exerted a more sus-
tained neurological recovery than the monotherapies and
might have important signiﬁcance for the treatment of TBI
[42].
More recently, studies have moved their focus on the
therapeutic eﬃcacy of agonists to PPAR-γ [24, 43]. Pioglita-
zone and rosiglitazone are both approved drugs for diabetes
treatment and have been shown to bind to PPAR-γ [24].
Sauerbeck et al. hypothesized that pioglitazone would pro-
mote neuroprotection in a rat controlled cortical impact
model of TBI where the drug was administered every 24
hours beginning 15 minutes after injury [44]. Treatment
withpioglitazoneresultedinsigniﬁcantlyimprovedcognitive
function, reduced lesion size, and prevented the activation
of microglia, compared to the vehicle-treated animals [44,
45]. Similar beneﬁcial eﬀects could be demonstrated for ro-
siglitazone both in traumatic brain and spine injury [27,
34, 46, 47]. Taken together, PPAR-γ agonists have been
shown to exert a wide range of anti-inﬂammatory, anti-oxid-
ative, and anti-apoptotic eﬀects and were like that able to
counteract the main pathophysiological events occurring
in the development of secondary CNS injury [27, 44, 47–
49]. These observations could strengthen the idea that the
ﬁeld of application of PPAR-γ agonists could be expanded
from antidiabetic drugs to therapeutic agents counteracting
neuroinﬂammation and improving the outcome of patients
with traumatic CNS injuries.
In addition to synthetic PPAR agonists, a protective
role of cannabinoids on the sequelae of CNS trauma has
been suggested in recent years [50–52]. The group of can-
nabinoids consists of endogenous ligands, such as 2-
arachidonyl glycerol (2-AG), and synthetic drugs like dex-
anabinol (HU-211) [53]. After TBI in mice, elevated levels
o f2 - A Gc o u l db ed e t e c t e d[ 54]. Administration of 2-
AG to mice after experimental head injury suppressed the
release of reactive oxygen species and proinﬂammatory cyto-
kines and improved clinical recovery [54, 55]. Similar to
that, the synthetic cannabinoid HU-211 revealed as a cere-
broprotectant attenuating breakdown of the blood-brain
barrier and production of cytokines [56, 57]. Recent studies
have provided evidence that an increasing number of anti-
inﬂammatory actions of cannabinoids are not mediated
by the classical cannabinoid receptors but are induced
by agonistic action of cannabinoids to PPARs [53, 58].4 PPAR Research
Oleylethanolamide that is structurally related to the endoge-
nous cannabinoid anandamide was found to bind to PPAR-
α,a n dΔ9-tetrahydrocannbinol (THC), the active ingredient
of cannabis, has been described as a PPAR-γ ligand [59,
60]. Interestingly, the mechanism by which 2-AG suppresses
interleukin-2 expression was linked to targeting PPAR-γ and
was independent of cannabinoid receptors [58]. Due to the
promising anti-inﬂammatory properties of cannabinoids, a
randomized phase II and III clinical trial was initiated that
aimed to test HU-211 in the treatment of brain trauma
[52, 61, 62]. In the study patients treated with HU-211
achieved signiﬁcantly decreased intracranial pressure, and
a trend towards better neurological outcome was observed
[61].
In summary, numerous attempts of targeting PPARs
both by cannabinoids and by synthetic PPAR ligands have
revealed the huge neuroprotective ability of PPAR agonism.
Further studies will have to examine if administration of
a single PPAR ligand or a combination of cannabinoids
with synthetic PPAR agonists might have the potential to be
introduced in the clinic of traumatic CNS injury.
4. PPARs in Ischemia/Reperfusion Injury
Ischemia/reperfusion (I/R) injury represents a challenging
pathophysiological condition with serious clinical implica-
tions, in a broad ﬁeld of conditions such as organ trans-
plantation, compartment syndrome, myocardial infarction,
stroke, and hemorrhagic, traumatic, or septic shock [5, 63].
Tissue ischemia together with subsequent reperfusion has
been shown to trigger a whole cascade of inﬂammatory
events that, if not counteracted in early stages, result in cell
necrosis with irreversible tissue damage in aﬀected organs
[7]. Research eﬀorts in recent years have provided increasing
evidence that PPARs represent major regulators of this in-
ﬂammatory response; PPAR activation could be shown to
restrict inﬂammation and exert multiple beneﬁcial eﬀects
against ischemia/reperfusion injury [7, 15]. Consequently,
pharmacologicalagentstargetingPPARshavebeensuggested
as potential therapeutics for the treatment of I/R.
Similar as described for traumatic CNS injuries, a strong
relationship between PPAR tissue expression and I/R injury
couldbedemonstrated.InkidneyI/R,PPARγ expressionwas
strongly increased in endothelial cells, interstitial cells, and
collecting ducts of the kidney peaking from 1.5 to 5 hours
afterreperfusion[64,65].SimilarupregulationofPPARγ was
detected in the cortical peri-infarct area after focal cerebral
ischemia in rats [66]. Interestingly, Lee and colleagues have
recently found in a model of transient cerebral ischemia
that PPARγ-immunoreactivity in the hippocampus was
colocalized with microglial cells indicating a high functional
state of microglia in the ischemic brain [67].
In recent years, animal studies of I/R injury in various
organs have revealed a crucial role of PPARs in reducing or
even preventing tissue injury and organ dysfunction after
ischemia and reperfusion [15, 68, 69]. Consequently, a wide
variety of natural and synthetic PPAR agonists was tested
in experimental I/R models and was shown to signiﬁcant-
ly improve the outcome of I/R injury [5, 70, 71]. The
mechanisms of tissue protection by PPAR ligands have been
thought to be multifactorial [7], since these agonists can
interact with variable parameters of the IR-induced inﬂam-
matory cascade and inhibit multiple targets on the way to
injury progression, as outlined in Figure 2.T h ep r o p o s e d
mechanisms of action include: (i) reduced expression of
adhesion molecules like ICAM-1 and p-selectin on endothe-
lial cells [72, 73], (ii) decreased vascular permeability with
suppressed edema formation [74], (iii) inhibited release of
proinﬂammatory mediators like cytokines and chemokines
[68, 75], (iv) reduced activation of inﬂammatory cells like
neutrophils [72, 76], (v) decreased formation of reactive
oxygen species [77, 78], (vi) suppressed cell apoptosis and
necrosis [79, 80], and (vii) inhibited platelet aggregation
and thrombus formation [81]. Similar as described for CNS
injuries, the majority of these anti-inﬂammatory eﬀects is
initiated by PPAR-induced suppression of transcription fac-
tors (mainly NF-κB) and subsequent inhibition of proin-
ﬂammatory gene transcription (Figure 2)[ 35, 69, 70, 80].
In addition to the mentioned general eﬀects of PPAR ac-
tivation on the inﬂammatory response in I/R (Figure 2),
numeroustissue-speciﬁcimpactsofPPARagonistshavebeen
described in diﬀerent organ systems (reviewed in [5, 15]).
4.1. Renal I/R. Renal ischemia is a major cause of acute
renal failure that is complicated by the fact that subsequent
reperfusion of hypoxic tissue may cause additional injury
[82]. Agonists to all three PPAR isoforms, PPARα,P P A R β/δ,
and PPARγ, signiﬁcantly reduced tissue damage in mice sub-
jected to kidney ischemia and reperfusion [77, 83, 84]. This
renoprotection was reﬂected in attenuation of cortical and
medullary necrosis, reduction of histological signs of renal
damage, and ﬁnally in strongly increased renal function with
lowered serum creatinine and urea nitrogen levels [69, 85,
86]. The mechanisms underlying these beneﬁcial properties
may consist in induction of fatty acid β-oxidation enzymes
byPPARsinkidneytissue;transgenicmiceexpressingPPARα
in the proximal tubule were shown to exert increased fatty
acid oxidation and were protected from I/R-induced kidney
failure [87, 88].
4.2. Pulmonary I/R. I/R injury of the lung still occurs in 20%
of patients after lung transplantation and remains the main
cause of death during the ﬁrst month after transplantation
[89]. Application of the synthetic PPARγ ligand pioglitazone
or the natural PPARγ agonist 15-deoxy-Δ12,14-prostaglandin
J2 (15d-PGJ2) before ischemia could attenuate lung I/R
injury in rats [70, 74]. A recent study of Okada et al. indi-
cated that PPARγ activation suppresses activation of the
zinc ﬁnger transcription factor early growth response gene-1
(Egr-1) that has a crucial role in the inﬂammatory response
in ischemic vessels [70]. Thus, as a consequence of PPARγ
activation, the induction of Egr-1 target genes such as
interleukin-1β is prevented, IR-associated leukostasis is de-
creased, and overall survival is improved [70].
4.3. Gastrointestinal I/R. Intestinal and gastric I/R injuries
are serious clinical conditions resulting from abdominalPPAR Research 5
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Figure 2: Schematic depiction of the inﬂammatory events occurring during the pathophysiology of ischemia/reperfusion (I/R) injury,
and potential pharmacological eﬀects of PPAR ligands, by inhibition of nuclear transcription factors. See text for detailed explanations.
Abbreviations: PPAR, peroxisome proliferator-activated receptor; CNS, central nervous system; NF-κB, nuclear factor-κB; AP-1, activator
protein-1; NFAT, nuclear factor of activated T cells; STAT-3, signal transducer and activator of transcription-3.
aneurism, acute mesenteric ischemia, small bowel transplan-
tation, or shock [90]. In rodent models of intestinal I/R,
all three isotypes of PPAR agonists showed profound anti-
inﬂammatory, anti-oxidative and anti-apoptotic eﬀects that
were associated with a decreased I/R-induced mortality rate
[68, 72, 80]. Similar to that, pioglitazone and rosiglitazone
suppressedgastricmucosalerosionanddamageingastricI/R
rats [78, 91]. Additionally, beneﬁcial eﬀects of early enteral
nutrition after gut I/R could be linked to PPAR induction.
The nutrition component glutamine was reported to exert
gut protection by activation of PPARγ [92, 93].
4.4. Ischemic Brain Injury. Ischemic cerebrovascular disease
represents the third leading cause of death and is one of
the major causes of neurological dysfunction and disability
[94]. Various studies have suggested that PPAR agonists may
prevent or decrease the severity of both focal and global
ischemia [66, 95]. In humans, stroke incidence was reduc-
ed when men with coronary heart disease and low HDL
and LDL cholesterol values were treated with the ﬁbrate
and PPARα agonist gemﬁbrozil [96]. Application of PPARα,
PPARβ/δ,a n dP P A R γ ligands in transient ischemic brain
injury of rodents resulted in signiﬁcantly attenuated neu-
ronal damage and reduced infarction volume, increased
cerebral blood ﬂow, and improved neurological outcome
parameters [71, 97–99]. This neuroprotection was observed
when animals were treated preventively before ischemia, at
the time of cerebral infarction, or shortly after that with a
time window of eﬃcacy of two hours after ischemia [73,
76, 100]. In contrast to transient ischemia, PPARγ activa-
tion failed to decrease infarction volume when the blood
ﬂowwasinterruptedpermanentlywithoutsubsequentreper-
fusion [101–103]. These ﬁndings support evidence that the
neuroprotective role of PPARγ is speciﬁc to events occurring
during reperfusion.
Overall, various studies provide evidence that ligands to
PPARs cause a substantial reduction of I/R injury in diverse
organsbyinterferingwithmultipletargetsoftheI/R-induced
inﬂammatory cascade.
5. PPARs inSepsis andShock
Shock and sepsis are serious complications of severely ill
patients in intensive care units that can ultimately lead to
multiple organ failure and death. There is now increasing
evidence that the immune response following severe trauma
is divided into two phases [4]. The early hyperinﬂammatory
state is characterized by an overactivation of the innate im-
mune system with increased priming of neutrophils and
extensive release of inﬂammatory mediators like cytokines
or reactive oxygen species. Often this ﬁrst period is followed
by a second immunosuppressive phase associated with the
attenuation of adaptive immunity and decreased T cell
function [3, 8].
The role of PPAR activation in modulating this post-
traumatic immune response is ambiguous and has been
described as “double-edged sword” [8]. Numerous preclin-
ical studies have supported central beneﬁcial eﬀects of PPAR
activationintheﬁrstproinﬂammatoryperiod[104–107].On
the other hand, PPARs have been shown to exert proapop-
totic and desensitizing characteristics on inﬂammatory cells
what might increase the susceptibility of the trauma patient6 PPAR Research
Table 1: Selected publications on experimental studies testing the anti-inﬂammatory eﬀects of PPAR ligands in various models of sepsis and
shock.
Pathological condition PPAR isotype/ligand Ligand-induced eﬀects Aﬀected signaling
pathway Reference
Endotoxic shock
PPARα/fenoﬁbrate
Decrease in coagulation activation
(monocyte tissue factor
expression), protection against
endothelial dysfunction
Not examined Wiel et al. [107]
PPARγ/rosiglitazone
Suppression of biomarkers for liver
and kidney injury and of cytokines,
inhibition of heart rate increase
N o te x a m i n e d W ue ta l .[ 110]
PPARγ/15d-PGJ2
Improvement of survival rate,
reduction of adhesion molecule
expression, and of neutrophil
inﬁltration in tissues
NF-κB, HSP (heat shock
protein) 70
Kaplan et al.
[104]
Hemorrhagic shock PPARγ/ciglitazone
Amelioration of mean arterial
pressure, reduction of plasma
cytokine levels, decrease of
apoptosis in lung and liver
NF-κB Chima et al.
[112]
Caspase-3, PI3/Akt
Chima et al.
[113],
Zingarelli et al.
[105]
PPARγ/15d-PGJ2
Attenuation of renal dysfunction
and of liver, lung, and intestine
injury
Not examined Abdelrahman
et al. [111]
Polymicrobial
sepsis/septic shock PPARβ/δ
Decrease in cytokine release,
attenuation of organ dysfunction,
reduced expression of inducible
nitric oxide synthase
Akt, GSK-3β, ERK1/2,
STAT-3, NF-κB
Kapoor et al.
[106]
Zingarelli et al.
[115]
PPARγ/ciglitazone and
15d-PGJ2
Amelioration of hypotension and
survival, decreased inﬂammatory
signs in lung, colon, and liver
NF-κB, AP-1 Zingarelli et al.
[114]
Multiple organ failure PPARβ/δ
Reduction of peritoneal exsudate
formation and of neutrophil
inﬁltration, attenuation of multiple
organ dysfunction syndrome
Not examined Galuppo et al.
[117]
PPARγ/rosiglitazone
Attenuation of peritoneal
exsudation and of organ injury and
dysfunction
Not examined Cuzzocrea et al.
[116]
to secondary infections during the immunosuppressive
phase [108, 109].
T h ep r o t e c t i v ep r o p e r t i e so fP P A Ra g o n i s t sh a v eb e e n
examined in multiple animal models of sepsis and shock
(Table 1)( r e vi e w e di n[ 8, 12]). Using intraperitoneal LPS in-
jection as a model for endotoxic shock in mice, Kaplan et al.
could demonstrate that endotoxin-induced inﬂammation
was associated with reduced expression of PPARγ and with
activation of NF-κB in the lung [104]. Treatment with
the natural PPARγ ligand 15d-PGJ2 signiﬁcantly improved
survival rate and attenuated inﬂammation signs by repress-
ing activation of NF-κB and enhancing the expression of
cytoprotective heat shock protein in the lung [104]. Similar
to that biomarkers of liver and kidney injury and inﬂamma-
tory cytokines were suppressed when PPARγ agonists were
applied before induction of endotoxic shock [110].
In hemorrhagic shock in rats, the PPARγ agonists 15d-
PGJ2 and ciglitazone ameliorated mean arterial pressure,
blunted neutrophil activation, and abolished dysfunction of
kidney, liver, lung, and intestine [111, 112]. These eﬀects
were mediated through inhibition of the NF-κBp a t h w a y .
Moreover, two recent studies have found that hemorrhaghic
shock-induced apoptosis in the liver and the lung can be de-
creased by ciglitazone treatment [105, 113]. Herein, atte-
nuation of lung apoptosis was associated with signiﬁcant
reduction in caspase-3 activity and increased phosphoryla-
tion of the prosurvival kinase Akt [113].
In a rodent model of polymicrobial sepsis, both PPARγ
and PPARβ/δ activation limited the extent of organ dysfunc-
tion caused by cecal ligation and puncture (CLP) [106, 114].
PPARβ/δ-deﬁcient mice suﬀered exaggerated lethality when
subjected to CLP and exhibited severe lung injury and higher
levels of TNFα [106, 115]. Application of a PPARβ/δ agonist
signiﬁcantly improved survival in polymicrobial sepsis by a
mechanism that might involve activation of Akt, inhibition
of the MAPK-ERK1/2-signaling pathway, and subsequent
suppression of NF-κBa c t i v i t y[ 106].PPAR Research 7
Multiple organ failure as a ﬁnal consequence of severe
shock and sepsis can be induced in mice by intraperitoneal
administration of zymosan. When animals were treated
with a PPARγ or PPARβ/δ agonist after zymosan injection,
peritoneal exude formation and neutrophil inﬁltration were
reduced, and lung, liver and pancreatic injury, and renal
dysfunction were attenuated [116, 117].
Besides of the classical PPAR agonists, endogenous fac-
tors have recently been shown to exert immunomodulatory
properties by activating PPARs in diﬀerent shock models.
C-peptide is a 31-amino acid peptide cleaved from insulin
during insulin synthesis that has been considered to have
minimal biological activity [118]. However, in vitro and in
vivo studies have now reported that C-peptide may stimu-
late PPARγ and thus modulate the inﬂammatory response
in ischemia/reperfusion and shock [119–121]. A study of
Vish et al. could demonstrate that treatment with C-
peptide improved survival rates and reduced plasma levels
of cytokines when mice were subjected to endotoxic shock
[121]. C-peptide also upregulated nuclear expression of
PPARγ and reduced phosphorylation of ERK-1 and -2 [121].
Moreover,inamodel ofhemorrhagicshockinrats,hypoten-
sion and lung inﬂammation were signiﬁcantly ameliorated
after C-peptide infusion what was associated with reduced
expression of AP-1 and NF-κB and activation of PPARγ
[122].
Similarly, the vasoactive hormone adrenomedullin has
been shown to be beneﬁcial in sepsis by abrogating the pro-
gression to irreversible shock. In addition to its vasodilatory
function, adrenomedullin decreases cytokines in the circula-
tion of septic animals what synergistically protects animals
from dying of sepsis [123]. These latter anti-inﬂammatory
eﬀects seem to be mediated by mechanisms involving
intracellular cAMP increase, followed by upregulation of
PPARγandsubsequentsuppressionofcytokinerelease[124].
In contrast to the multiple beneﬁcial properties of PPAR
agonism, recent studies have revealed additional eﬀects of
PPARactivationonimmunecellsthatmightcompromisethe
role of these cells in host defense. Neutrophils represent the
central cellular component in the sepsis-induced innate im-
mune response and were previously shown to express PPARγ
[125].TreatmentofisolatedneutrophilswithPPARγ agonists
resulted in a signiﬁcant reduction of neutrophil chemo-
tactic activity in vitro [109]. When sepsis was induced in
mice,chemotaxisofneutrophilswassuppressedcomparedto
healthy mice, but treatment with a PPARγ antagonist restor-
ed chemotactic activity to control levels [109]. Since neu-
trophil expression was increased in septic patients and mice,
the authors of the study suggested that the inhibited migra-
tion of neutrophils during sepsis might occur as a result of
PPARγ activation.
Similar to neutrophils, upregulation of PPARγ was ob-
served in T cells of septic patients [108]. These cells re-
sponded with apoptosis when they were exposed to PPARγ
agonists [108]. In an animal model of sepsis, sepsis-induced
T cell depletion was abrogated after application of a PPARγ
antagonist [126]. Consequently, a pivotal involvement of
PPARγ in T cell apoptosis was hypothesized what might
contribute to lymphocyte loss and breakdown of defense
mechanisms during sepsis.
Taken together, there is increasing evidence that PPAR
activation has multiple anti-inﬂammatory properties in
shock, sepsis, and multiple organ failure. However, PPARγ
agonismwasalsofoundtocontributetofunctionlossofneu-
trophils and depletion of lymphocytes what might be delete-
riousintheimmunosuppressivephaseofsepsis.Thisfacthas
to be taken in consideration when a potential therapeutical
use of PPAR agonists in the treatment of shock and sepsis is
discussed.
6.The Role of PPARs inWound
Healing Processes
After skin trauma and injury, wound healing is a life-saving
process during which the wound bed is covered with a
new protective epithelium. This healing process is mainly
divided into three phases. The initial inﬂammatory stage
is followed by proliferation and migration of keratinocytes
with reepithelialization of the wound [19]. In parallel, der-
mal repair involves activation and proliferation of ﬁbroblasts
and angiogenesis (remodeling phase) what ﬁnally results in
wound closure.
WhilePPARexpressionprogressivelydisappearsfromthe
interfollicular epidermis after birth, PPARα and PPARβ/δ
are reactivated in keratinocytes at the wound edges of
damaged skin [127]. Hereby, the upregulation of PPARα is
transient and correlates with the early inﬂammatory phase
of wound healing. A study of Michalik et al. could demon-
strate that PPARα−/− mice exert a transient delay of wound
healing during the ﬁrst 4 days after injury coinciding with
increased PPARα expression during the inﬂammatory stage
[127,128].Furthermore,boththerecruitmentofneutrophils
and monocytes was impaired in PPARα−/− mice. In contrast
to PPARα,P P A R β/δ expression persists throughout the
entire repair process and is correlated to keratinocyte prolif-
eration, adhesion, and migration in order to reepithelialize
the wounded area. Consistent to that, wound healing of
PPARβ+/− mice was delayed during the whole repair process,
and ﬁnal wound closure was postponed by two to three days
[127].
As outlined in Figure 3, the expression of PPARβ/δ dur-
ing wound healing is characterized by a speciﬁc time pattern
and is tightly regulated by signaling cascades, providing
both stimulatory and negative feedback mechanisms [18,
129]. Upon injury, proinﬂammatory cytokines like TNFα
activate the stress-associated protein kinase pathway and
induce AP-1 binding to the PPARβ/δ promotor, leading to
the stimulation of PPARβ/δ expression [130]. In the heal-
ing process, PPARβ/δ represses apoptosis cascades through
transcriptional upregulation of integrin-linked kinase (ILK)
and 3-phosphoinositide-dependent kinase-1 (PDK), and
consequent Akt-1 activation [131]. The resulting resistance
to cell death helps to maintain a suﬃcient number of viable
keratinocytes for reepithelialization. Moreover, PPARβ/δ
is implicated in keratinocyte adhesion and migration of
keratinocytes, two key processes during reepithelialization8 PPAR Research
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Figure 3: Role of PPARβ/δ expression in the wound healing
processes after tissue injury. See text for detailed explanations.
Abbreviations: PPAR, peroxisome proliferator-activated receptor;
TNFα,tumornecrosisfactorα;SAPK,stress-associatedproteinkinase;
AP-1, activator protein-1; PPAR, peroxisome proliferator-activated
receptor; TGFβ, transforming growth factor β; IL-1β, interleukin-1 β;
sIL-1ra, soluble interleukin-1 receptor antagonist.
[131, 132]. After the inﬂammatory and early reepithelial-
ization phase, during which PPARβ/δ expression is maxi-
mal, PPARβ/δ is progressively reduced in the epithelium.
The responsible antagonization process is initiated by
TGFβ-1/Smad3-mediated inhibition of AP-1 binding to the
PPARβ/δ promotorinthelatereepithelialization/remodeling
phase, resulting in downregulation of the PPARβ/δ gene
[133, 134]. Taken together, the healing process represents a
delicate balance between early proinﬂammatory signals trig-
gering PPARβ/δ expression and negative feedback pathways
at later stages of wound healing. Since both processes tem-
porally overlap, an intensive crosstalk between the two
signalingpathwaysissuggestedthatcontributetoﬁne-tuning
of wound closure [133].
In addition to the described anti-apoptotic properties,
PPARβ/δ also inﬂuences keratinocyte diﬀerentiation and
proliferation by to-date unknown mechanism. Chong et
al. could recently demonstrate that PPARβ/δ-dependent
interplay between the epidermis and dermis is essential
for controlling epidermal proliferation (Figure 3)[ 18, 135].
They found that interleukin-1 (IL-1) produced by ker-
atinocytes stimulates AP-1 transcription factor in dermal
ﬁbroblasts and consequently increases the production of
mitogenic factors that enhance keratinocyte proliferation.
In parallel, IL-1 activates PPARβ/δ expression in ﬁbroblasts,
which increases the production of the secreted IL-1 receptor
antagonist (sIL-1ra), a protein inhibiting IL-1 signaling. As a
consequence, the IL-1-induced production of mitogenic fac-
tors by ﬁbroblasts is reduced, and keratinocyte proliferation
isdecreasedwhenwoundclosurecomestoanend[135].This
study provides evidence that PPARβ/δ participates in regu-
lating epidermal proliferation via a paracrine mechanism.
In summary, eﬃciency in the wound healing process is
guaranteed both by interactions within the epidermis as well
as by epithelial-mesenchymal crosstalk. Thus, keratinocyte
diﬀerentiation and survival are provided in the early healing
process and, at the same time, exaggerated proliferation
and hypertrophic scarring are avoided in later stages. It has
been suggested that these insights into the coordination of
wound healing might contribute to develop better treatment
strategies for chronic wound disorders [18].
7. Conclusion
In summary, various studies have provided evidence that
PPARs have a substantial impact on reducing the extent of
post-injury inﬂammation after major trauma, mainly by the
suppression of the central transcription factor NF-κB. These
anti-inﬂammatory properties could be supported by the use
of synthetic and natural PPAR ligands in multiple animal
models of CNS trauma, I/R injury, and shock. Furthermore,
PPAR activation was found to be responsible for the
balance between diﬀerentiation, cell survival, and apoptosis
during wound healing. Synthetic PPAR ligands are readily
available from clinical trials in diabetes and hyperlipidemia.
The basic science studies described in this review article
provide a strong rationale for testing these pharmacological
compounds for their anti-inﬂammatory potential in the
clinical setting of posttraumatic hyperinﬂammation in the
near future.
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